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j ourna l homepage: www.eb iomed ic ine.comEditorialHospital-acquired Infections — A Clean Bill of Health?This yearmarks the 150th anniversary of theuntimely death of Ignaz
Semmelweis. His namemight be unfamiliar to many of you, but he was
a pioneer of antiseptic policy whose recommendations revolutionized
healthcare by limiting the spread of hospital-acquired infections (HAIs).
While working as a physician in Viennese obstetric clinics,
Semmelweis observed that the incidence of puerperal fever (caused
by a bacterial infection of the female reproductive tract) could be dras-
tically reduced when doctors washed their hands in chlorinated lime.
Helped by Pasteur's germ theory, which offered a scientiﬁc explanation
to Semmelweis' observational evidence, the practice of handwashing in
hospitals eventually earned widespread acceptance.
Despite this preventativemeasure, HAIs currently affect approximate-
ly 10% of patients throughout the USA and Europe, causing respiratory,
gastrointestinal, urinary tract, surgical site and blood-borne infections,
complicating recovery and contributing to patient mortality. Prolonged
hospital stays andadditional therapeutic interventions, oftenusing antibi-
otics, add to the ﬁnancial burden on already strained healthcare systems.
Complicating matters further, the drugs that have been routinely
used to treat many of these infections are losing their potency as bacte-
ria develop antibiotic resistance. The emergence of ‘superbugs’ that are
either intrinsically resistant, or acquire resistance by the transfer of ge-
netic material, is driven by the selection pressure imposed by antibiotic
use, allowing resistant bacteria to ﬂourish at the expense of their sensi-
tive counterparts. Compounding this situation is the fact that as bacteria
evolve mechanisms to bypass previously effective antibiotics, there is a
paucity of new antibiotics in development. This disparity threatens to
revert healthcare to a pre-antibiotic era, leading to a dire situation
with signiﬁcant public health ramiﬁcations. Recently, theWorld Health
Organization published “Worldwide country situation analysis: Response
to antimicrobial resistance”, highlighting the current situation and
outlining how best to address the issue on a global scale. On May 25,
2015, delegates at the World Health Assembly endorsed this global ac-
tion plan, urgingmember states tomake it a national priority andmobi-
lize additional resources for its implementation. Progress will be
reported to the Health Assembly in 2017.
Many factors have contributed to the escalation of antibiotic resis-
tance. From amedical practitioner's standpoint, inappropriate prescrip-
tion of antibiotics and complacent use of wide-spectrum antibiotics
have exerted selection pressure on a similarly broad group of microbes.
The general public plays a part when demanding antibiotics from their
doctors for self-limiting viral infections, failing to complete a full course
of antibiotics, or by propagating the black-market sales of antibiotics—
an immediate problem in developing countries. Crucially, farmers use
antibiotics as prophylaxis against infection and as a means to promote
the growth of their animals (although the latter practice is banned in
the EU), which expedites widespread resistance. Governments have,
until recently, seemed ill-informed of the impending danger, or chosehttp://dx.doi.org/10.1016/j.ebiom.2015.06.009
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Finally, for their part, pharmaceutical companies re-directed efforts
towards more proﬁtable therapeutic areas at the cost of antibiotic
development. In sum, antibiotic resistance was an inevitability — an
impending crisis that nobody wanted to acknowledge.
There is still hope, but it relies on a concerted effort from all of the
parties mentioned above. Scientists must invest in the development of
new antibiotics and governments should support this enterprise and
provide robust public health policy. One such initiative, launched on
June 10, 2015, is Antibiotic Discovery Global. This network of experts
from the industry and academia aim to use their knowledge base and in-
frastructure to support global antibiotic development and discovery. An-
other strategy to stimulate change is to incentivize the process. On June
2, 2015, The U.S. Department of Health and Human Services proposed
a competition in which up to $20 million would be made available for
the delivery of diagnostics that identify bacterial infections, thereby pro-
moting antibiotic stewardship. Proposals are currently being considered.
A recent innovation resulting from an academic-pharma partnership
was the identiﬁcation of a new class of antibiotic. Spearheaded by Kim
Lewis at Northeastern University, Boston, MA, USA, and reported in Na-
ture on January 22, 2015, teixobactin was discovered by screening bac-
teria in soil. Teixobactin was able to kill problematic Gram-positive
bacteria by inhibiting cell wall synthesis, without producing newly re-
sistant strains — a resistance-resistant antibiotic had been found.
These results have been received with tentative optimism. Not only is
this the ﬁrst novel class of antibiotic to be described in decades, but it
is also hoped that the screening methodology can be used to identify
manymore, including those against Gram-negative bacteria that are re-
sistant to virtually all modern antibiotics.
Semmelweis' life ended tragically. After becoming increasingly
frustrated by the resistance of the medical community to adopt hand
disinfection into clinical practice, he wrote a series of offensive open
letters to prominent obstetricians accusing them of being irresponsible
murderers. His behavior became erratic, hewas ostracized professional-
ly and became detached from his family. In the summer of 1865,
Semmelweis was invited to visit a Viennese insane asylum, where he
was beaten and incarcerated against his will. Two weeks later, aged
47, Semmelweis died from a gangrenous wound.
The act of eschewing new knowledge because it contradicts
entrenched norms is often called a ‘Semmelweis reﬂex’. Hopefully the
current antibiotic crisis is no longer beingmetwith a Semmelweis reﬂex
and the gap between antibiotic resistance and antibiotic development
will begin to close. However, this situation will require effective collab-
oration and a desire to embrace innovation — something Semmelweis
would have beneﬁted from 150 years ago.
EBioMedicine-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
